Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene blue for COVID-19-associated acute respiratory distress syndrome
IRCT20200409047007N2Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methylene blue in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoint: One-month mortality rate. Started Sep 2021; status: completed.
02
Drugs
methylene blue
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on IRCT20200409047007N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200409047007N2.